ALK (ALKB/ OMX: ALK B / AKABY / AKBLF), a Denmark based provider of allergy prevention, diagnosis and treatment, announced on Monday that it has received U.S. FDA approval for its new line of AccuTest Allergy Skin Testing Devices, designed to enhance the accuracy and reliability of allergy testing and diagnosis.
This product line includes single-prick and multi-head devices, AccuTest-1, AccuTest-8 and AccuTest-10, as well as allergen well trays, aimed at improving diagnostic precision and patient comfort.
The multi-head applicators, available in 8-head and 10-head configurations, offer ergonomic designs with ribbed grips and larger top surface areas for more uniform pressure application, contributing to consistent results. The single-prick device, AccuTest-1, and the multi-head models feature smaller tines to improve accuracy and minimize discomfort.
AccuTest allergen well trays, compatible with the devices, feature a non-slip base and air-tight locking mechanism to prevent contamination, ensuring stability and accuracy during testing.
A recent study highlighted the AccuTest line's precision and its potential to reduce device variability, which could improve the reliability of allergy test results.
Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial
Amytrx Therapeutics names new directors
Inimmune signs research collaboration with Boston Children's Hospital